These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 25095884)

  • 21. Primary prevention implantable cardioverter-defibrillators and survival in older women.
    Zeitler EP; Hellkamp AS; Fonarow GC; Hammill SC; Curtis LH; Hernandez AF; Al-Khalidi HR; Curtis JP; Heidenreich PA; Anstrom KJ; Peterson ED; Mark DB; Hammill BG; Sanders GD; Al-Khatib SM
    JACC Heart Fail; 2015 Feb; 3(2):159-67. PubMed ID: 25543969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes?
    Hess PL; Mi X; Curtis LH; Wilkoff BL; Hegland DD; Al-Khatib SM
    Heart Rhythm; 2013 Aug; 10(8):1127-33. PubMed ID: 23773989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry).
    Daimee UA; Aslam F; Parzynski CS; Desai NR; Curtis JP
    Am J Cardiol; 2021 Sep; 155():64-71. PubMed ID: 34315569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.
    Marzec LN; Peterson PN; Bao H; Curtis JP; Masoudi FA; Varosy PD; Bradley SM
    JAMA Cardiol; 2017 May; 2(5):561-565. PubMed ID: 28122073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death: Prevalence and Impact on Mortality.
    Green AR; Leff B; Wang Y; Spatz ES; Masoudi FA; Peterson PN; Daugherty SL; Matlock DD
    Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):23-30. PubMed ID: 26715650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry.
    Thijssen J; van den Akker van Marle ME; Borleffs CJ; van Rees JB; de Bie MK; van der Velde ET; van Erven L; Schalij MJ
    Pacing Clin Electrophysiol; 2014 Jan; 37(1):25-34. PubMed ID: 23998638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention.
    Peterson PN; Varosy PD; Heidenreich PA; Wang Y; Dewland TA; Curtis JP; Go AS; Greenlee RT; Magid DJ; Normand SL; Masoudi FA
    JAMA; 2013 May; 309(19):2025-34. PubMed ID: 23677314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient, physician, and procedural factors influencing the use of defibrillation testing during initial implantable cardioverter defibrillator insertion: findings from the NCDR®.
    Russo AM; Wang Y; Al-Khatib SM; Curtis JP; Lampert R
    Pacing Clin Electrophysiol; 2013 Dec; 36(12):1522-31. PubMed ID: 23981009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry.
    Dewland TA; Pellegrini CN; Wang Y; Marcus GM; Keung E; Varosy PD
    J Am Coll Cardiol; 2011 Aug; 58(10):1007-13. PubMed ID: 21867834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry.
    Thomas IC; Wang Y; See VY; Minges KE; Curtis JP; Hsu JC
    Heart Rhythm; 2019 May; 16(5):733-740. PubMed ID: 30414460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.
    Charytan DM; Patrick AR; Liu J; Setoguchi S; Herzog CA; Brookhart MA; Winkelmayer WC
    Am J Kidney Dis; 2011 Sep; 58(3):409-17. PubMed ID: 21664735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry.
    Gadler F; Valzania C; Linde C
    Europace; 2015 Jan; 17(1):69-77. PubMed ID: 25336667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
    Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement.
    Heidenreich PA; Tsai V; Curtis J; Wang Y; Turakhia MP; Masoudi FA; Varosy PD; Goldstein MK
    Am Heart J; 2015 Aug; 170(2):281-289.e2. PubMed ID: 26299225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
    Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
    J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
    Pun PH; Hellkamp AS; Sanders GD; Middleton JP; Hammill SC; Al-Khalidi HR; Curtis LH; Fonarow GC; Al-Khatib SM
    Nephrol Dial Transplant; 2015 May; 30(5):829-35. PubMed ID: 25404241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence, correlates, and temporal trends in antiarrhythmic drug use at discharge after implantable cardioverter defibrillator placement (from the National Cardiovascular Data Registry [NCDR]).
    Dev S; Peterson PN; Wang Y; Curtis JP; Varosy PD; Masoudi FA
    Am J Cardiol; 2014 Jan; 113(2):314-20. PubMed ID: 24216126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation among hospitals in selection of higher-cost, "higher-tech," implantable cardioverter-defibrillators: data from the National Cardiovascular Data Registry (NCDR) Implantable Cardioverter/Defibrillator (ICD) Registry.
    Lampert R; Wang Y; Curtis JP
    Am Heart J; 2013 Jun; 165(6):1015-1023.e2. PubMed ID: 23708175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.